189 related articles for article (PubMed ID: 25088806)
1. Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.
Boone SD; Baumgartner KB; Baumgartner RN; Connor AE; Pinkston CM; Rai SN; Riley EC; Hines LM; Giuliano AR; John EM; Stern MC; Torres-Mejía G; Wolff RK; Slattery ML
Cancer Causes Control; 2014 Nov; 25(11):1461-71. PubMed ID: 25088806
[TBL] [Abstract][Full Text] [Related]
2. Associations between genetic variants in the TGF-β signaling pathway and breast cancer risk among Hispanic and non-Hispanic white women.
Boone SD; Baumgartner KB; Baumgartner RN; Connor AE; Pinkston CM; John EM; Hines LM; Stern MC; Giuliano AR; Torres-Mejia G; Brock GN; Groves FD; Kerber RA; Wolff RK; Slattery ML
Breast Cancer Res Treat; 2013 Sep; 141(2):287-97. PubMed ID: 24036662
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
Haiman CA; Dossus L; Setiawan VW; Stram DO; Dunning AM; Thomas G; Thun MJ; Albanes D; Altshuler D; Ardanaz E; Boeing H; Buring J; Burtt N; Calle EE; Chanock S; Clavel-Chapelon F; Colditz GA; Cox DG; Feigelson HS; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn JN; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Le Marchand L; Lenner P; Lund E; Panico S; Peeters PH; Pike MC; Riboli E; Tjonneland A; Travis R; Trichopoulos D; Wacholder S; Ziegler RG
Cancer Res; 2007 Mar; 67(5):1893-7. PubMed ID: 17325027
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Johansson H; Gray KP; Pagani O; Regan MM; Viale G; Aristarco V; Macis D; Puccio A; Roux S; Maibach R; Colleoni M; Rabaglio M; Price KN; Coates AS; Gelber RD; Goldhirsch A; Kammler R; Bonanni B; Walley BA;
Breast Cancer Res; 2016 Nov; 18(1):110. PubMed ID: 27825388
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study.
Slattery ML; John EM; Torres-Mejia G; Herrick JS; Giuliano AR; Baumgartner KB; Hines LM; Wolff RK
Int J Cancer; 2013 Jun; 132(12):2928-39. PubMed ID: 23180569
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in estrogen and progesterone pathway genes and breast cancer risk: an exploration of tumor subtype-specific effects.
Nyante SJ; Gammon MD; Kaufman JS; Bensen JT; Lin DY; Barnholtz-Sloan JS; Hu Y; He Q; Luo J; Millikan RC
Cancer Causes Control; 2015 Jan; 26(1):121-31. PubMed ID: 25421376
[TBL] [Abstract][Full Text] [Related]
7. Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study.
Xia Z; Baumgartner KB; Baumgartner RN; Boone SD; Hines LM; John EM; Wolff R; Slattery ML; Connor AE
Breast Cancer Res Treat; 2018 Apr; 168(2):443-455. PubMed ID: 29190005
[TBL] [Abstract][Full Text] [Related]
8. Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
Kopp TI; Jensen DM; Ravn-Haren G; Cohen A; Sommer HM; Dragsted LO; Tjonneland A; Hougaard DM; Vogel U
BMC Cancer; 2016 Apr; 16():283. PubMed ID: 27102200
[TBL] [Abstract][Full Text] [Related]
9. The Interaction between Genetic Ancestry and Breast Cancer Risk Factors among Hispanic Women: The Breast Cancer Health Disparities Study.
Hines LM; Sedjo RL; Byers T; John EM; Fejerman L; Stern MC; Baumgartner KB; Giuliano AR; Torres-Mejia G; Wolff RK; Harrall KK; Slattery ML
Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):692-701. PubMed ID: 27932594
[No Abstract] [Full Text] [Related]
10. Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
Chen C; Sakoda LC; Doherty JA; Loomis MM; Fish S; Ray RM; Lin MG; Fan W; Zhao LP; Gao DL; Stalsberg H; Feng Z; Thomas DB
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3457-66. PubMed ID: 19064562
[TBL] [Abstract][Full Text] [Related]
11. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
Talbott KE; Gammon MD; Kibriya MG; Chen Y; Teitelbaum SL; Long CM; Gurvich I; Santella RM; Ahsan H
Breast Cancer Res Treat; 2008 Oct; 111(3):481-7. PubMed ID: 17975727
[TBL] [Abstract][Full Text] [Related]
12. Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
Cai Q; Kataoka N; Li C; Wen W; Smith JR; Gao YT; Shu XO; Zheng W
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):27-32. PubMed ID: 18199708
[TBL] [Abstract][Full Text] [Related]
13. Positive association of polymorphisms in estrogen biosynthesis gene, CYP19A1, and metabolism, GST, in breast cancer susceptibility.
Ramalhinho AC; Fonseca-Moutinho JA; Breitenfeld Granadeiro LA
DNA Cell Biol; 2012 Jun; 31(6):1100-6. PubMed ID: 22300440
[TBL] [Abstract][Full Text] [Related]
14. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
[TBL] [Abstract][Full Text] [Related]
17. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States.
Slattery ML; Curtin K; Baumgartner R; Sweeney C; Byers T; Giuliano AR; Baumgartner KB; Wolff RR
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):747-55. PubMed ID: 17416766
[TBL] [Abstract][Full Text] [Related]
18. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study.
Slattery ML; John EM; Stern MC; Herrick J; Lundgreen A; Giuliano AR; Hines L; Baumgartner KB; Torres-Mejia G; Wolff RK
Breast Cancer Res Treat; 2013 Aug; 140(3):587-601. PubMed ID: 23912956
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study.
Slattery ML; Herrick JS; Torres-Mejia G; John EM; Giuliano AR; Hines LM; Stern MC; Baumgartner KB; Presson AP; Wolff RK
Carcinogenesis; 2014 Aug; 35(8):1750-9. PubMed ID: 24670917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
